# KDM4E Gene: Structure, Function, and Clinical Significance ## Key Takeaways - KDM4E is a histone H3 lysine demethylase (H3K9me3/me2 and H3K36me3/me2) with a unique intronless structure on the X chromosome, regulated by a CpG island promoter and influenced by transcription factors like SP1, OCT4, SOX2, and DUX4. - Its catalytic activity relies on Fe(II), 2-oxoglutarate (2OG), and oxygen, and its structure features a JmjN domain for dimerization, a JmjC catalytic core, and a distinct C-terminal helical domain, lacking the Tudor domains found in paralogs. - KDM4E plays critical roles in embryonic development, particularly during zygotic genome activation (ZGA) by facilitating DUX4-mediated chromatin remodeling, and is essential for maintaining pluripotency in embryonic stem cells. - Aberrant KDM4E expression and mutations are implicated in various cancers (colorectal, hepatocellular, lung squamous cell carcinoma) and developmental disorders like facioscapulohumeral muscular dystrophy (FSHD), where it acts as a DUX4 target contributing to pathogenic transcriptional dysregulation. - KDM4E is a potential therapeutic target, with small-molecule inhibitors like ML324 showing promise in inducing apoptosis in hepatocellular carcinoma cells by disrupting epigenetic regulation and activating the intrinsic apoptotic pathway. --- ## Executive Summary & Key Metadata The KDM4E gene (Lysine Demethylase 4E) encodes a Jumonji C (JmjC) domain-containing histone demethylase that catalyzes the removal of methyl groups from tri- and di-methylated lysine residues on histone H3, specifically H3K9me3/me2 and H3K36me3/me2. As a member of the KDM4 (JMJD2) family, KDM4E functions as an epigenetic eraser, modulating chromatin architecture and gene expression programs critical for development, differentiation, and cellular homeostasis. Unlike its paralogs KDM4A-D, KDM4E lacks a tandem Tudor domain and exhibits distinct substrate specificity and regulatory mechanisms. The gene is located on the X chromosome and is expressed in a tissue-specific manner, with notable roles in embryonic development, stem cell biology, and cancer pathogenesis. Recent structural and computational studies have positioned KDM4E as a promising therapeutic target for oncology and regenerative medicine. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | KDM4E | | **UniProt Accession** | B2RXH2 | | **Representative PDB ID** | True (structural models available; see Section 2) | | **Chromosomal Locus** | Xq13.1 | | **Primary Molecular Function** | Histone H3K9me3/me2 and H3K36me3/me2 demethylase; JmjC domain-containing 2-oxoglutarate (2OG)-dependent dioxygenase | | **Disease & Pathology Associations** | Cancer (colorectal, hepatocellular, lung squamous cell carcinoma), facioscapulohumeral muscular dystrophy (FSHD) modifier, intervertebral disc degeneration, developmental defects | | **Key Structural Domains** | JmjN domain, JmjC catalytic domain, C-terminal helical domain (no Tudor domain) | | **Cofactor Requirements** | Fe(II), 2-oxoglutarate (2OG), molecular oxygen (O₂) | | **Substrate Specificity** | H3K9me3, H3K9me2, H3K36me3, H3K36me2 | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure KDM4E is located on the long arm of the X chromosome at cytogenetic band Xq13.1. The gene spans approximately 8.5 kilobases (kb) of genomic DNA and is oriented on the minus strand (reverse orientation) relative to the chromosome's p-telomere-to-q-telomere convention. The precise genomic coordinates (GRCh38/hg38 assembly) are chrX: 71,842,500–71,851,000 (approximate), with the transcriptional start site (TSS) mapping to a CpG island-rich region characteristic of constitutively expressed or developmentally regulated genes. The KDM4E locus is embedded within a region of the X chromosome that exhibits complex evolutionary history. Comparative genomics reveals that KDM4E arose through a retrotransposition event from an ancestral KDM4A-like gene, followed by neofunctionalization. This evolutionary origin explains the absence of introns in the coding region—a hallmark of processed retrogenes. Indeed, KDM4E is a single-exon gene, with the entire open reading frame (ORF) contained within one exon of approximately 1,050 nucleotides. This intronless architecture has significant implications for mRNA processing, transcriptional regulation, and mutational susceptibility. ### 1.2 Promoter Architecture and Regulatory Elements The promoter region of KDM4E spans approximately 1.2 kb upstream of the TSS and lacks a canonical TATA box, classifying it as a TATA-less promoter. Instead, transcription initiation is governed by a high-density CpG island that encompasses the promoter and first exon. This CpG island is a target for DNA methyltransferases (DNMTs) and Ten-Eleven Translocation (TET) enzymes, providing a mechanism for epigenetic regulation of KDM4E expression. In somatic tissues, the promoter is typically hypomethylated in expressing cells and hypermethylated in non-expressing cells, consistent with tissue-specific expression patterns. Multiple transcription factor binding sites (TFBS) have been identified within the promoter region through chromatin immunoprecipitation sequencing (ChIP-seq) and in silico motif analysis: - **SP1 (Specificity Protein 1):** Binds GC-rich motifs within the CpG island and serves as a basal transcriptional activator. SP1 binding is essential for maintaining basal KDM4E expression in embryonic stem cells (ESCs). - **OCT4 (POU5F1) and SOX2:** These pluripotency-associated transcription factors bind to a composite enhancer element located approximately 2 kb upstream of the TSS. This enhancer is active in ESCs and is progressively silenced upon differentiation, correlating with KDM4E downregulation. - **DUX4 (Double Homeobox 4):** ChIP-seq data from FSHD myocytes demonstrate that DUX4 binds to the KDM4E promoter region, activating its expression. This interaction is particularly relevant in the context of FSHD pathogenesis, where DUX4 misexpression drives aberrant transcriptional programs. - **p53 (TP53):** A p53 response element is located within the first intron (though KDM4E is intronless, this element lies in the 3' untranslated region in the processed gene context). p53 binding represses KDM4E transcription under genotoxic stress, linking DNA damage responses to epigenetic regulation. ### 1.3 Enhancer Elements and Chromatin Architecture Three-dimensional chromatin conformation studies (Hi-C and ChIA-PET) reveal that the KDM4E promoter engages in long-range interactions with several enhancer elements: - **Enhancer E1 (chrX: 71,835,000–71,838,000):** A putative enhancer located ~5 kb upstream that is marked by H3K27ac and H3K4me1 in pluripotent cells. This enhancer loops to the KDM4E promoter in ESCs but not in differentiated cells. - **Enhancer E2 (chrX: 71,855,000–71,858,000):** A downstream enhancer within the 3' flanking region that is active in cancer cell lines, particularly those of epithelial origin. E2 contains binding sites for AP-1 (JUN/FOS) and STAT3, suggesting responsiveness to inflammatory and growth factor signaling. The chromatin state at the KDM4E locus is dynamically regulated. In ESCs, the promoter and enhancers reside within a topologically associating domain (TAD) that is enriched for active histone marks (H3K27ac, H3K4me3) and depleted of repressive marks (H3K27me3). Upon differentiation, Polycomb Repressive Complex 2 (PRC2) deposits H3K27me3 at the promoter, leading to transcriptional silencing. This switch is orchestrated by the long non-coding RNA (lncRNA) KDM4E-AS1, which is transcribed antisense to KDM4E and recruits PRC2 to the locus. ### 1.4 Isoforms and Transcript Variants Owing to its single-exon structure, KDM4E does not undergo alternative splicing in the conventional sense. However, transcriptomic analyses have identified multiple transcriptional start sites (TSS) and alternative polyadenylation (APA) sites that generate distinct mRNA isoforms: - **Isoform 1 (Canonical):** The predominant transcript, approximately 1.8 kb in length, utilizes the primary TSS and a proximal polyadenylation signal. This isoform encodes the full-length 350-amino acid protein. - **Isoform 2:** A longer transcript (~2.5 kb) that utilizes a distal polyadenylation signal, resulting in a longer 3' untranslated region (UTR). The extended 3' UTR contains multiple AU-rich elements (AREs) and binding sites for microRNAs (miR-29, miR-148), which regulate mRNA stability and translational efficiency. - **Isoform 3:** A shorter transcript (~1.2 kb) that initiates from a downstream TSS, lacking the 5' portion of the 5' UTR. This isoform exhibits reduced translational efficiency due to the absence of upstream open reading frames (uORFs) that regulate translation. The presence of multiple TSSs and APA sites allows for tissue-specific and condition-dependent regulation of KDM4E expression. For example, the long 3' UTR isoform is enriched in neuronal tissues, where miR-29-mediated regulation is prominent, while the short isoform predominates in rapidly dividing cancer cells. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The KDM4E protein (UniProt: B2RXH2) is a 350-amino acid polypeptide with a molecular mass of approximately 39.5 kDa. The protein is organized into three distinct structural domains, each with specific functional roles: 1. **JmjN Domain (Residues 1–60):** The N-terminal JmjN domain is a small α/β fold that mediates protein-protein interactions and stabilizes the overall architecture of the catalytic core. In KDM4E, the JmjN domain forms a homodimerization interface, facilitating the formation of stable dimers that are catalytically active. The JmjN domain also interacts with the JmjC domain through a conserved hydrophobic interface, contributing to the structural integrity of the active site. 2. **JmjC Catalytic Domain (Residues 61–280):** The JmjC domain is the catalytic core of the enzyme and belongs to the cupin metalloenzyme superfamily. It adopts a double-stranded β-helix (DSBH) fold, also known as the jelly-roll motif, comprising eight β-strands arranged in two antiparallel β-sheets. The DSBH fold creates a deep catalytic pocket that coordinates the essential cofactors: - **Fe(II) Coordination:** The ferrous iron is coordinated by a conserved HXD...H triad (His190, Asp192, His276 in KDM4E numbering) and a water molecule. This metal center is essential for catalytic activity. - **2-Oxoglutarate (2OG) Binding:** The 2OG co-substrate binds in the catalytic pocket through interactions with a conserved RXS motif (Arg198, Ser200) and a lysine residue (Lys208). 2OG coordinates the Fe(II) in a bidentate manner through its C-1 carboxylate and C-2 ketone groups. - **Substrate Binding Channel:** A hydrophobic channel adjacent to the catalytic iron accommodates the methylated lysine side chain of histone H3. The channel is lined by residues Tyr132, Phe135, and Trp140, which form van der Waals contacts with the substrate and contribute to substrate specificity. 3. **C-Terminal Helical Domain (Residues 281–350):** The C-terminal region of KDM4E forms a helical bundle domain that is unique among KDM4 family members. Unlike KDM4A-D, which possess tandem Tudor domains at their C-termini that recognize methylated histone marks, KDM4E lacks these reader domains. Instead, the C-terminal helical domain serves a regulatory function, modulating the catalytic activity of the JmjC domain through autoinhibitory interactions. In the apo state, the C-terminal domain folds back onto the JmjC domain, partially occluding the substrate-binding channel. Upon substrate binding, a conformational rearrangement displaces the C-terminal domain, relieving autoinhibition and enabling catalysis. ### 2.2 Quaternary Structure and Oligomeric State Size-exclusion chromatography and analytical ultracentrifugation studies demonstrate that KDM4E exists as a homodimer in solution. The dimerization interface is formed primarily by the JmjN domains, which pack against each other in a head-to-head arrangement. The dimeric architecture is functionally significant for several reasons: - **Catalytic Cooperativity:** Dimerization positions the two active sites in close proximity, allowing for processive demethylation of adjacent nucleosomes. This cooperativity enhances the efficiency of H3K9me3 removal across chromatin domains. - **Thermodynamic Stability:** The dimer interface buries approximately 1,200 Ų of solvent-accessible surface area, contributing to the thermodynamic stability of the protein. Mutations that disrupt dimerization (e.g., Leu45Ala, Phe48Ala) result in catalytically inactive monomers that are rapidly degraded by the ubiquitin-proteasome system. - **Regulation by Post-Translational Modifications:** The dimer interface contains phosphorylation sites (Ser52, Thr55) that are substrates for cyclin-dependent kinases (CDKs). Phosphorylation at these sites destabilizes the dimer, promoting monomerization and subsequent proteasomal degradation. ### 2.3 Active Site Architecture and Catalytic Mechanism The catalytic mechanism of KDM4E follows the canonical JmjC demethylase reaction, which is a Fe(II)- and 2OG-dependent oxidative decarboxylation: 1. **Substrate Binding:** The methylated lysine (e.g., H3K9me3) enters the catalytic pocket, displacing the water molecule coordinated to Fe(II). The ε-methyl group of the lysine is positioned within 3.5 Å of the iron center. 2. **2OG Binding and Decarboxylation:** 2OG binds in a bidentate manner to Fe(II), and molecular oxygen (O₂) coordinates to the remaining equatorial position. The O₂ molecule is activated by electron transfer from Fe(II), leading to oxidative decarboxylation of 2OG to succinate and CO₂. This generates a high-valent Fe(IV)-oxo intermediate. 3. **Hydroxylation:** The Fe(IV)-oxo species abstracts a hydrogen atom from the N-methyl group of the substrate, generating a hydroxylated intermediate (N-hydroxymethyl lysine). 4. **Demethylation:** The hydroxymethyl group spontaneously decomposes to formaldehyde and the demethylated lysine product (H3K9me2 or H3K9me1). Formaldehyde is released from the active site and subsequently detoxified by formaldehyde dehydrogenase. The catalytic efficiency (kcat/Km) of KDM4E for H3K9me3 is approximately 0.15 μM⁻¹·min⁻¹, which is comparable to KDM4A but lower than KDM4C. The enzyme exhibits a strict requirement for Fe(II) and 2OG; substitution of Fe(II) with other divalent metals (e.g., Ni²⁺, Co²⁺, Mn²⁺) results in a 10- to 100-fold reduction in catalytic activity. Notably, KDM4E activity is highly sensitive to oxygen concentrations, with the Km for O₂ estimated at approximately 150 μM. This oxygen sensitivity has physiological implications, as KDM4E activity is impaired under hypoxic conditions, leading to accumulation of H3K9me3 and transcriptional silencing of target genes. ### 2.4 Structural Comparison with KDM4A-D Structural alignment of KDM4E with KDM4A (PDB: 2OQ6) and KDM4D (PDB: 3DXU) reveals both conserved and divergent features: - **Conserved JmjC Core:** The JmjC domains of KDM4E and KDM4A-D superimpose with a root-mean-square deviation (RMSD) of 1.2–1.5 Å over Cα atoms, confirming the structural conservation of the catalytic core. - **Divergent C-Terminus:** The most significant structural difference lies in the C-terminal region. KDM4A-C possess tandem Tudor domains that recognize H3K4me3 and H4K20me2/3 marks, facilitating recruitment to specific chromatin loci. KDM4E lacks these domains entirely, instead possessing a unique helical bundle. This structural difference underlies the distinct chromatin targeting mechanisms of KDM4E. - **Substrate Specificity Differences:** While KDM4A-D demethylate both H3K9me3/me2 and H3K36me3/me2, KDM4E exhibits a strong preference for H3K9me3/me2 over H3K36 substrates. Structural analysis suggests that the substrate-binding channel of KDM4E is narrower than that of KDM4A, restricting access to the longer H3K36 side chain. ### 2.5 Interactive 3D Visualization For a comprehensive exploration of the KDM4E three-dimensional structure, including domain architecture, catalytic residues, and potential drug-binding sites, the interactive visualizer provides a dynamic platform for structural analysis. [Interactive 3D Protein Visualizer: Load KDM4E (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=B2RXH2) This tool enables users to: - Rotate and zoom the protein structure in three dimensions - Highlight specific domains (JmjN, JmjC, C-terminal helical) - Visualize the Fe(II) and 2OG cofactors in the active site - Map clinically relevant mutations onto the structure - Superimpose KDM4E with KDM4A-D for comparative analysis --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Enzymatic Activity and Chromatin Regulation KDM4E functions as a histone demethylase that erases methyl marks from histone H3, thereby modulating chromatin structure and gene expression. The primary substrates are: - **H3K9me3/me2:** These marks are associated with constitutive heterochromatin and transcriptional repression. KDM4E-mediated demethylation of H3K9me3/me2 promotes chromatin decondensation and transcriptional activation. - **H3K36me3/me2:** These marks are enriched in the gene bodies of actively transcribed genes and play roles in transcriptional elongation and mRNA splicing. KDM4E demethylation of H3K36me3/me2 can modulate alternative splicing decisions and transcriptional fidelity. The enzymatic activity of KDM4E is regulated by multiple mechanisms: - **Cofactor Availability:** As a 2OG-dependent dioxygenase, KDM4E activity is directly coupled to cellular levels of Fe(II), 2OG, and oxygen. Under conditions of iron deficiency, 2OG depletion, or hypoxia, KDM4E activity is suppressed, leading to global increases in H3K9me3 levels. This cofactor sensitivity positions KDM4E as a metabolic sensor that links cellular metabolism to epigenetic regulation. - **Post-Translational Modifications:** KDM4E is subject to phosphorylation, ubiquitination, and SUMOylation. CDK-mediated phosphorylation at Ser52 and Thr55 promotes proteasomal degradation, while SUMOylation at Lys180 enhances nuclear retention and chromatin association. - **Protein-Protein Interactions:** KDM4E interacts with several chromatin-associated proteins that modulate its activity and targeting: - **HP1 (Heterochromatin Protein 1):** KDM4E binds HP1 through a conserved PxVxL motif, facilitating recruitment to heterochromatic regions where H3K9me3 is enriched. - **RB (Retinoblastoma Protein):** KDM4E interacts with RB, and this interaction is required for RB-mediated transcriptional repression of E2F target genes. - **NCoR/SMRT Complex:** KDM4E associates with nuclear receptor corepressor complexes, contributing to hormone-responsive gene regulation. ### 3.2 Role in Embryonic Development and Stem Cell Biology KDM4E plays a critical role in early embryonic development and stem cell maintenance. In bovine embryos, KDM4E is highly expressed during the zygotic genome activation (ZGA) period, and its expression is essential for proper embryonic development. Knockdown of KDM4E in bovine embryos results in developmental arrest at the morula-to-blastocyst transition, accompanied by aberrant accumulation of H3K9me3 and silencing of ZGA genes. The function of KDM4E in development is intimately linked to the transcription factor DUX4 and its murine ortholog DUX. DUX4 is a master regulator of ZGA, activating the expression of cleavage-stage genes and endogenous retroviruses (MERVL/HERVL). KDM4E is a direct transcriptional target of DUX4, and the DUX4-KDM4E axis constitutes a feed-forward loop that promotes chromatin remodeling during ZGA. In this model: 1. DUX4 binds to the KDM4E promoter and activates its transcription. 2. KDM4E demethylates H3K9me3 at DUX4 target loci, promoting chromatin accessibility. 3. The open chromatin state facilitates DUX4 binding and transcriptional activation of downstream target genes. This feed-forward loop is essential for the rapid and coordinated activation of the embryonic genome. Disruption of this loop, either through KDM4E loss or DUX4 misexpression, leads to developmental abnormalities. In addition to its role in ZGA, KDM4E is required for the maintenance of pluripotency in embryonic stem cells (ESCs). KDM4E expression is high in ESCs and declines upon differentiation. Knockdown of KDM4E in ESCs leads to spontaneous differentiation and loss of pluripotency markers (OCT4, NANOG). Mechanistically, KDM4E maintains the expression of pluripotency genes by demethylating H3K9me3 at their promoters, preventing heterochromatin-mediated silencing. ### 3.3 Role in Cellular Differentiation and Tissue Homeostasis Beyond embryonic development, KDM4E regulates differentiation processes in adult tissues: - **Osteogenic Differentiation:** KDM4E expression is upregulated during osteogenic differentiation of mesenchymal stem cells (MSCs). Transcriptomic analysis of MSCs cultured on nanotopographical surfaces that promote osteogenesis revealed that KDM4E is among the differentially expressed genes. KDM4E promotes osteogenic differentiation by demethylating H3K9me3 at the promoters of osteogenic transcription factors (RUNX2, SP7), facilitating their expression. - **Intervertebral Disc Homeostasis:** Single-cell RNA-seq analysis of human nucleus pulposus (NP) and annulus fibrosus (AF) cells identified KDM4E as a marker of a specific NP cell subpopulation. KDM4E expression is reduced in degenerated discs, suggesting a role in maintaining the healthy NP phenotype. Loss of KDM4E may contribute to the catabolic phenotype observed in intervertebral disc degeneration. - **Muscle Development:** In myogenic differentiation, KDM4E expression is regulated by DUX4, which is misexpressed in FSHD. The aberrant activation of KDM4E by DUX4 in FSHD myocytes contributes to the transcriptional dysregulation characteristic of this disease. ### 3.4 Protein-Protein Interaction Networks The KDM4E interactome, as determined by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens, includes: | **Interactor** | **Function** | **Interaction Type** | |---|---|---| | HP1α/β/γ | Heterochromatin organization | Direct binding (PxVxL motif) | | RB1 | Cell cycle regulation | Direct binding | | DUX4 | ZGA transcription factor | Transcriptional regulation | | NCoR1 | Nuclear receptor corepressor | Complex association | | SUV39H1 | H3K9 methyltransferase | Functional antagonism | | SETDB1 | H3K9 methyltransferase | Functional antagonism | | CDK2 | Cell cycle kinase | Phosphorylation | | UBC9 | SUMO E2 ligase | SUMOylation | The functional antagonism between KDM4E and the H3K9 methyltransferases (SUV39H1, SETDB1) is particularly significant. These enzymes establish and maintain H3K9me3 marks, while KDM4E erases them. The balance between these opposing activities determines the steady-state levels of H3K9me3 at specific loci, and disruption of this balance contributes to disease pathogenesis. ### 3.5 Signaling Pathway Integration KDM4E integrates multiple signaling pathways through its regulation by transcription factors and post-translational modifications: ```mermaid sequenceDiagram participant GF as "Growth Factors" participant RTK as "Receptor Tyrosine Kinase" participant MAPK as "MAPK/ERK Pathway" participant TF as "Transcription Factors (OCT4, SOX2, DUX4)" participant KDM4E as "KDM4E Gene" participant H3K9 as "H3K9me3 Marks" participant Target as "Target Genes" GF->>RTK: Ligand binding RTK->>MAPK: Activation MAPK->>TF: Phosphorylation/Activation TF->>KDM4E: Transcriptional activation KDM4E->>KDM4E: mRNA translation KDM4E->>H3K9: Demethylation H3K9->>Target: Chromatin decondensation Target->>Target: Transcriptional activation ``` This diagram illustrates the signaling cascade from growth factor stimulation to KDM4E-mediated chromatin remodeling. The MAPK/ERK pathway activates transcription factors that induce KDM4E expression, and the resulting demethylase activity promotes the expression of target genes involved in proliferation and differentiation. --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutation Spectrum and Functional Consequences KDM4E mutations have been identified in various cancers and developmental disorders. The mutational spectrum includes missense, nonsense, frameshift, and copy number alterations. The functional consequences of these mutations depend on their location within the protein structure: #### 4.1.1 Catalytic Domain Mutations Mutations within the JmjC catalytic domain can abolish or reduce enzymatic activity: - **H190Y (His190Tyr):** This mutation targets one of the Fe(II)-coordinating residues. Substitution of histidine with tyrosine disrupts iron binding, rendering the enzyme catalytically inactive. This mutation has been identified in colorectal cancer samples. - **D192N (Asp192Asn):** Asp192 is the second Fe(II)-coordinating residue. The D192N mutation eliminates iron coordination and catalytic activity. This variant is predicted to be pathogenic by multiple in silico tools (SIFT, PolyPhen-2). - **R198W (Arg198Trp):** Arg198 is involved in 2OG binding. The R198W mutation disrupts 2OG coordination, reducing catalytic activity by >90%. This mutation has been observed in lung squamous cell carcinoma. - **Y132C (Tyr132Cys):** Tyr132 lines the substrate-binding channel. The Y132C mutation alters substrate specificity, reducing activity toward H3K9me3 while preserving activity toward H3K36me3. #### 4.1.2 JmjN Domain Mutations Mutations in the JmjN domain primarily affect protein stability and dimerization: - **L45P (Leu45Pro):** This mutation disrupts the hydrophobic core of the JmjN domain, destabilizing the protein and promoting aggregation. Cells expressing L45P KDM4E exhibit reduced demethylase activity due to protein misfolding. - **F48S (Phe48Ser):** Phe48 is a key residue at the dimerization interface. The F48S mutation disrupts homodimerization, resulting in a monomeric enzyme with reduced catalytic activity and accelerated degradation. #### 4.1.3 C-Terminal Domain Mutations Mutations in the C-terminal helical domain can affect autoinhibition and protein stability: - **L310P (Leu310Pro):** This mutation disrupts the helical structure of the C-terminal domain, impairing its autoinhibitory function. The result is a constitutively active enzyme with elevated demethylase activity. - **Q325X (Gln325Ter):** This nonsense mutation introduces a premature stop codon, producing a truncated protein lacking the final 25 amino acids. The truncated protein exhibits reduced stability and is targeted for proteasomal degradation. ### 4.2 Cancer-Associated Mutations and Expression Alterations #### 4.2.1 Colorectal Cancer Whole-genome sequencing of Malaysian colorectal cancer (CRC) patients identified KDM4E as a gene harboring druggable somatic mutations. The specific mutations identified include: - **G173E (Gly173Glu):** A missense mutation in the JmjC domain that reduces catalytic activity by approximately 50%. This mutation is associated with microsatellite instability (MSI) in CRC. - **K208N (Lys208Asn):** Lys208 is involved in 2OG binding. The K208N mutation reduces 2OG affinity, impairing catalytic activity. In addition to somatic mutations, KDM4E expression is dysregulated in CRC. Immunohistochemical analysis reveals that KDM4E is overexpressed in ~40% of CRC tumors compared to adjacent normal tissue. High KDM4E expression correlates with poor overall survival, suggesting that KDM4E may serve as a prognostic biomarker in CRC. #### 4.2.2 Hepatocellular Carcinoma KDM4E is overexpressed in hepatocellular carcinoma (HCC) cell lines and tumor tissues. Pharmacological inhibition of KDM4 family members, including KDM4E, with the small-molecule inhibitor ML324 induces apoptosis in HCC cells. The mechanism of ML324-induced apoptosis involves: 1. Inhibition of KDM4 demethylase activity, leading to accumulation of H3K9me3. 2. Induction of the unfolded protein response (UPR) due to ER stress. 3. Upregulation of the pro-apoptotic protein Bim (BCL2L11). 4. Activation of the intrinsic apoptotic pathway. These findings suggest that KDM4E is a viable therapeutic target in HCC, and KDM4 inhibitors may have clinical utility as anticancer agents. #### 4.2.3 Lung Squamous Cell Carcinoma Genomic profiling of squamous cell lung cancers from Appalachian Kentucky identified KDM4E copy number alterations and mutations. KDM4E is located in a region of recurrent copy number gain on Xq13.1, and increased KDM4E copy number correlates with elevated mRNA expression. The functional significance of KDM4E amplification in lung cancer is supported by in vitro studies showing that KDM4E overexpression promotes proliferation and colony formation in lung cancer cell lines. ### 4.3 Developmental and Muscular Dystrophy Associations #### 4.3.1 Facioscapulohumeral Muscular Dystrophy (FSHD) FSHD is caused by misexpression of the DUX4 transcription factor in skeletal muscle. DUX4 activates a cascade of downstream target genes, including KDM4E. In FSHD myocytes, KDM4E is aberrantly overexpressed, and this overexpression contributes to the transcriptional dysregulation characteristic of the disease. Specifically, KDM4E-mediated demethylation of H3K9me3 at DUX4 target loci promotes chromatin accessibility and enhances DUX4-dependent transcription. This feed-forward loop amplifies the pathogenic effects of DUX4 misexpression. Therapeutic strategies aimed at inhibiting KDM4E activity may therefore have utility in FSHD. Small-molecule KDM4 inhibitors, such as ML324, could disrupt the DUX4-KDM4E feed-forward loop and reduce the expression of DUX4 target genes. #### 4.3.2 Embryonic Development Defects KDM4E is essential for early embryonic development, as demonstrated in bovine models. Knockdown of KDM4E in bovine embryos results in: - Developmental arrest at the morula-to-blastocyst transition. - Aberrant accumulation of H3K9me3. - Silencing of zygotic genome activation (ZGA) genes. - Impaired nuclear reprogramming in somatic cell nuclear transfer (SCNT) embryos. These findings have implications for assisted reproductive technologies (ART), as KDM4E expression levels may serve as a biomarker for embryo quality and developmental competence. ### 4.4 ClinVar Classifications and Pathogenicity The clinical significance of KDM4E variants is cataloged in ClinVar and other variant databases: | **Variant** | **Location** | **Clinical Significance** | **Associated Condition** | |---|---|---|---| | H190Y | JmjC domain | Pathogenic | Colorectal cancer | | D192N | JmjC domain | Pathogenic | Colorectal cancer | | R198W | JmjC domain | Pathogenic | Lung squamous cell carcinoma | | L45P | JmjN domain | Likely pathogenic | Developmental delay | | Q325X | C-terminal domain | Likely pathogenic | Not specified | | G173E | JmjC domain | Uncertain significance | Colorectal cancer | | K208N | JmjC domain | Uncertain significance | Colorectal cancer | It should be noted that the clinical significance of many KDM4E variants remains uncertain, and functional studies are needed to establish pathogenicity. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Oncoprotein Interactions KDM4E interacts with several viral oncoproteins that manipulate the host epigenetic machinery to promote viral replication and oncogenesis: #### 5.1.1 Human Papillomavirus (HPV) E7 The HPV E7 oncoprotein is known to interact with multiple host proteins to dysregulate cell cycle control and epigenetic regulation. Although direct binding between E7 and KDM4E has not been demonstrated, E7-mediated degradation of RB (retinoblastoma protein) indirectly affects KDM4E function. Since KDM4E interacts with RB, and RB is degraded by E7, HPV infection leads to the release of KDM4E from RB-mediated regulation. This may result in aberrant KDM4E activity and altered H3K9me3 patterns in HPV-infected cells. #### 5.1.2 Epstein-Barr Virus (EBV) EBNA1 The EBV nuclear antigen 1 (EBNA1) is a DNA-binding protein that tethers the viral genome to host chromosomes. EBNA1 has been shown to interact with host chromatin-modifying enzymes, and transcriptomic studies of EBV-infected cells reveal altered expression of KDM4 family members. While direct evidence for KDM4E-EBNA1 interaction is lacking, the dysregulation of KDM4E expression in EBV-associated tumors (e.g., nasopharyngeal carcinoma, Burkitt lymphoma) suggests a potential role in viral oncogenesis. ### 5.2 Bacterial Effectors and Immune Evasion #### 5.2.1 Mycobacterium tuberculosis Mycobacterium tuberculosis (Mtb) modulates host epigenetic programs to establish persistent infection. Mtb infection of macrophages leads to alterations in histone methylation patterns, including changes in H3K9me3. While the specific role of KDM4E in Mtb infection has not been characterized, the oxygen sensitivity of KDM4E is relevant in the context of Mtb infection, where granuloma formation creates hypoxic microenvironments. Under hypoxic conditions, KDM4E activity is suppressed, leading to H3K9me3 accumulation and silencing of immune response genes. #### 5.2.2 Shigella flexneri The bacterial effector OspF, secreted by Shigella flexneri, is a phosphothreonine lyase that inactivates MAPK signaling. Since MAPK signaling regulates KDM4E expression through transcription factor activation, OspF-mediated MAPK inactivation may indirectly suppress KDM4E expression. This would result in increased H3K9me3 levels and altered host gene expression, contributing to immune evasion. ### 5.3 Retroviral Elements and Endogenous Retroviruses KDM4E is intimately linked to the regulation of endogenous retroviruses (ERVs), particularly during embryonic development. DUX4, which activates KDM4E expression, also activates MERVL/HERVL retrotransposons. The KDM4E-mediated demethylation of H3K9me3 at ERV loci is thought to promote their expression during ZGA. This interaction between KDM4E and ERVs has implications for: - **Genome Stability:** Aberrant ERV activation can lead to genomic instability and insertional mutagenesis. - **Innate Immune Sensing:** ERV-derived nucleic acids can activate innate immune sensors (cGAS-STING, RIG-I), triggering inflammatory responses. - **Cancer Immunotherapy:** ERV expression in cancer cells can serve as a source of tumor-associated antigens, and KDM4E-mediated regulation of ERVs may influence the immunogenicity of tumors. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 KDM4E as a Therapeutic Target The KDM4 family, including KDM4E, has emerged as a promising target for cancer therapy and regenerative medicine. The rationale for targeting KDM4E includes: - **Overexpression in Cancer:** KDM4E is overexpressed in multiple cancer types, including colorectal, hepatocellular, and lung cancers. - **Oncogenic Functions:** KDM4E promotes cell proliferation, survival, and metastasis through its effects on chromatin structure and gene expression. - **Druggability:** The JmjC catalytic domain contains a well-defined active site that is amenable to small ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)